CA2175282A1 - Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer - Google Patents

Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer

Info

Publication number: CA2175282A1
Authority: CA; Canada
Prior art keywords: hyaluronic acid; sodium hyaluronate; dosage; cancer; administration
Prior art date: 1996-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002175282A

Other languages

English (en)

Inventor

Rudolf Edgar Falk

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hyal Pharmaceutical Corp

Original Assignee

Hyal Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-29

Filing date

1996-04-29

Publication date

1997-10-30

1996-04-29 Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp

1996-04-29 Priority to CA002175282A priority Critical patent/CA2175282A1/fr

1997-04-25 Priority to ZA9703622A priority patent/ZA973622B/xx

1997-04-28 Priority to AU25644/97A priority patent/AU2564497A/en

1997-04-28 Priority to PCT/CA1997/000283 priority patent/WO1997040841A1/fr

1997-04-29 Priority to ARP970101754A priority patent/AR006892A1/es

1997-10-30 Publication of CA2175282A1 publication Critical patent/CA2175282A1/fr

Status Abandoned legal-status Critical Current

Links

229920002674 hyaluronan Polymers 0.000 title claims abstract description 167
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 160
229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 160
238000011282 treatment Methods 0.000 title claims abstract description 56
206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
201000011510 cancer Diseases 0.000 title claims abstract description 42
238000000034 method Methods 0.000 claims abstract description 34
150000003839 salts Chemical class 0.000 claims abstract description 25
239000003085 diluting agent Substances 0.000 claims abstract description 22
239000003814 drug Substances 0.000 claims abstract description 22
239000002253 acid Substances 0.000 claims abstract description 8
229940124597 therapeutic agent Drugs 0.000 claims abstract description 8
229920002385 Sodium hyaluronate Polymers 0.000 claims description 38
229940010747 sodium hyaluronate Drugs 0.000 claims description 38
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 38
238000002560 therapeutic procedure Methods 0.000 claims description 22
239000013543 active substance Substances 0.000 claims description 20
239000002246 antineoplastic agent Substances 0.000 claims description 17
229940127089 cytotoxic agent Drugs 0.000 claims description 16
238000001990 intravenous administration Methods 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 12
238000003556 assay Methods 0.000 claims description 9
239000008174 sterile solution Substances 0.000 claims description 9
239000002158 endotoxin Substances 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
230000005484 gravity Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
239000008223 sterile water Substances 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
239000011780 sodium chloride Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 28
201000010099 disease Diseases 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
230000000694 effects Effects 0.000 description 18
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 18
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 12
238000002512 chemotherapy Methods 0.000 description 12
229940079593 drug Drugs 0.000 description 12
229960002949 fluorouracil Drugs 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
230000004044 response Effects 0.000 description 10
230000003442 weekly effect Effects 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
229930003268 Vitamin C Natural products 0.000 description 7
235000010323 ascorbic acid Nutrition 0.000 description 7
239000011668 ascorbic acid Substances 0.000 description 7
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 7
229940099552 hyaluronan Drugs 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
229960000905 indomethacin Drugs 0.000 description 7
238000012360 testing method Methods 0.000 description 7
239000011718 vitamin C Substances 0.000 description 7
235000019154 vitamin C Nutrition 0.000 description 7
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
229960005070 ascorbic acid Drugs 0.000 description 6
239000002254 cytotoxic agent Substances 0.000 description 6
231100000599 cytotoxic agent Toxicity 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000006872 improvement Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
206010027476 Metastases Diseases 0.000 description 5
230000037396 body weight Effects 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229940123457 Free radical scavenger Drugs 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
230000003187 abdominal effect Effects 0.000 description 4
229940041181 antineoplastic drug Drugs 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000002659 cell therapy Methods 0.000 description 4
239000006071 cream Substances 0.000 description 4
229960003883 furosemide Drugs 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
229910001385 heavy metal Inorganic materials 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
244000005700 microbiome Species 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000002516 radical scavenger Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
206010053240 Glycogen storage disease type VI Diseases 0.000 description 3
206010027457 Metastases to liver Diseases 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
208000009956 adenocarcinoma Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229910052785 arsenic Inorganic materials 0.000 description 3
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
-1 methyl CCNU Chemical compound 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
229940126701 oral medication Drugs 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229960001603 tamoxifen Drugs 0.000 description 3
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010006002 Bone pain Diseases 0.000 description 2
102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
108010036941 Cyclosporins Proteins 0.000 description 2
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
241000792859 Enema Species 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
102100023122 Glycylpeptide N-tetradecanoyltransferase 2 Human genes 0.000 description 2
101710081889 Glycylpeptide N-tetradecanoyltransferase 2 Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000010159 IgA glomerulonephritis Diseases 0.000 description 2
206010021263 IgA nephropathy Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
208000015634 Rectal Neoplasms Diseases 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000000061 acid fraction Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
230000000118 anti-neoplastic effect Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
238000009583 bone marrow aspiration Methods 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
229960001927 cetylpyridinium chloride Drugs 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
238000011393 cytotoxic chemotherapy Methods 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
230000009429 distress Effects 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
239000007920 enema Substances 0.000 description 2
229940095399 enema Drugs 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000003779 hair growth Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
229960004752 ketorolac Drugs 0.000 description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
238000002350 laparotomy Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000003908 liver function Effects 0.000 description 2
238000007449 liver function test Methods 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
208000037819 metastatic cancer Diseases 0.000 description 2
208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
229960003632 minoxidil Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
229940087419 nonoxynol-9 Drugs 0.000 description 2
229920004918 nonoxynol-9 Polymers 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000008685 targeting Effects 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
241000282709 Aotus trivirgatus Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108010074604 Epoetin Alfa Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
108010013214 Hyaluronan Receptors Proteins 0.000 description 1
102000018866 Hyaluronan Receptors Human genes 0.000 description 1
102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241001071864 Lethrinus laticaudis Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010063916 Metastatic gastric cancer Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
238000003287 bathing Methods 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
208000020670 canker sore Diseases 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
208000013116 chronic cough Diseases 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000012325 curative resection Methods 0.000 description 1
230000006837 decompression Effects 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
201000006585 gastric adenocarcinoma Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
108010003425 hyaluronan-mediated motility receptor Proteins 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
229960004384 ketorolac tromethamine Drugs 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000011545 laboratory measurement Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
238000011248 postoperative chemotherapy Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000012113 quantitative test Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940049529 sodium hyaluronate 20 mg/ml Drugs 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000012905 visible particle Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

CA002175282A 1996-04-29 1996-04-29 Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer Abandoned CA2175282A1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
CA002175282A CA2175282A1 (fr)	1996-04-29	1996-04-29	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
ZA9703622A ZA973622B (en)	1996-04-29	1997-04-25	Use of forms of hyaluronic acid (HA) for the treatment of cancer.
AU25644/97A AU2564497A (en)	1996-04-29	1997-04-28	Use of formes f hyaluronic acid (ha) for the treatment of cancer
PCT/CA1997/000283 WO1997040841A1 (fr)	1996-04-29	1997-04-28	Emploi de formes d'acide hyaluronique (ha) pour therapie anticancereuse
ARP970101754A AR006892A1 (es)	1996-04-29	1997-04-29	Uso de formas del acido hialuronico (ha) para el tratamiento del cancer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002175282A CA2175282A1 (fr)	1996-04-29	1996-04-29	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer

Publications (1)

Publication Number	Publication Date
CA2175282A1 true CA2175282A1 (fr)	1997-10-30

Family

ID=4158095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002175282A Abandoned CA2175282A1 (fr)	1996-04-29	1996-04-29	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer

Country Status (5)

Country	Link
AR (1)	AR006892A1 (fr)
AU (1)	AU2564497A (fr)
CA (1)	CA2175282A1 (fr)
WO (1)	WO1997040841A1 (fr)
ZA (1)	ZA973622B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5888984A (en) *	1994-05-12	1999-03-30	Dermal Research Laboratories, Inc.	Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
DK1140198T3 (da)	1999-01-13	2008-03-10	Alchemia Oncology Pty Ltd	Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
DE60034667T2 (de)	1999-02-01	2008-03-13	Dermal Research Laboratories, Inc.	Pharmazeutische zusammensetzung aus komplexen kohlenhydraten und deren anwendung
US6472379B1 (en)	1999-03-15	2002-10-29	Trustees Of Boston University	Angiogenesis inhibition
AUPQ879500A0 (en) *	2000-07-14	2000-08-10	Meditech Research Limited	Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
AU760404B2 (en) *	2000-07-14	2003-05-15	Alchemia Oncology Pty Limited	Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US7879824B2 (en)	2001-07-31	2011-02-01	Dermal Research Laboratories, Inc.	Methods of preventing or treating diseases and conditions using complex carbohydrates
NZ533078A (en) *	2000-07-31	2006-11-30	Dermal Res Lab Inc	Preventing or treating diseases associated with allergies, autoimmunity and adhesion, metastatic and coronary cascades using complex carbohydrates, in particular hyaluronic acid
AU2002325635C1 (en) *	2001-08-27	2008-09-25	Alchemia Oncology Pty Limited	Improved therapeutic protocols
CA2458856C (fr) *	2001-08-27	2011-02-15	Meditech Research Limited	Protocoles therapeutiques ameliores
ITPD20020271A1 (it)	2002-10-18	2004-04-19	Fidia Farmaceutici	Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
JP5465431B2 (ja)	2005-07-27	2014-04-09	アルケミアオンコロジーピーティーワイリミテッド	ヒアルロナンを用いる治療プロトコル
WO2007028196A1 (fr)	2005-09-07	2007-03-15	Alchemia Oncology Pty Limited	Compositions thérapeutiques comprenant de l’hyaluronane et des anticorps therapeutiques, et procédes thérapeutiques
US9375447B2 (en) *	2013-03-14	2016-06-28	National Cheng Kung University	Modified hyaluronan and uses thereof in cancer treatment
CN105311051A (zh)	2014-05-26	2016-02-10	陈松源	具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6117A (ja) *	1984-06-11	1986-01-06	Seikagaku Kogyo Co Ltd	ムコ多糖系癌転移抑制剤
US5262403A (en) *	1986-03-10	1993-11-16	Board Of Regents, The University Of Texas System	Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5464942A (en) *	1990-07-24	1995-11-07	Seikagaku Kogyo Kabushiki Kaisha	Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
CA2122519C (fr) *	1994-04-29	2001-02-20	Rudolf Edgar Dr. Falk	Traitement du cancer et prevention des metastases
AU6362594A (en) *	1993-03-10	1994-09-26	Miles Inc.	Hyaluronic acid used as a cancer treatment

1996
- 1996-04-29 CA CA002175282A patent/CA2175282A1/fr not_active Abandoned
1997
- 1997-04-25 ZA ZA9703622A patent/ZA973622B/xx unknown
- 1997-04-28 AU AU25644/97A patent/AU2564497A/en not_active Abandoned
- 1997-04-28 WO PCT/CA1997/000283 patent/WO1997040841A1/fr not_active Ceased
- 1997-04-29 AR ARP970101754A patent/AR006892A1/es unknown

Also Published As

Publication number	Publication date
WO1997040841A1 (fr)	1997-11-06
ZA973622B (en)	1997-11-25
AR006892A1 (es)	1999-09-29
AU2564497A (en)	1997-11-19

Legal Events

Date	Code	Title	Description
1996-04-29	EEER	Examination request
2000-01-18	FZDE	Dead

Publication	Publication Date	Title
JP3256761B2 (ja)	2002-02-12	症状及び疾病の治療
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
CA2175282A1 (fr)	1997-10-30	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
JPH09512797A (ja)	1997-12-22	癌の治療および転移の予防
EP0873128A1 (fr)	1998-10-28	Administration orale de quantites efficaces de formes de l'acide hyaluronique
EP0874624B1 (fr)	2003-12-03	Ligands des recepteurs a l'acide hyaluronique et leur utilisation dans le traitement des tumeurs et de la restenose
US5817644A (en)	1998-10-06	Targeting of dosages of medicine and therapeutic agents
AU727001B2 (en)	2000-11-30	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
CA2167044C (fr)	2001-08-07	Administration par voie orale de quantites efficaces de certaines formes d'acide hyaluronique
CA2205692A1 (fr)	1998-11-16	Methode pour administrer un agent therapeutique, utilisant des formes appropriees d'acide hyaluronique en combinaison avec l'electroporation
AU6173599A (en)	2000-03-09	Treatment of conditions and disease
CA2131130A1 (fr)	1996-03-01	Modulation de l'activite cellulaire
HK1005985B (en)	2003-02-14	Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
CZ288292B6 (en)	2001-05-16	Compound therapeutic preparations intended for treatment of diseases or states of tissues comprising insufficiently perfused tissues and pathological tissues of human being
CA2166154A1 (fr)	1997-06-28	Agents liants et utilisation correspondante
CA2193921A1 (fr)	1998-06-24	Administration orale de quantites efficaces de formes d'acide hyaluronique repondant a diverses normes